Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PrNMI is a highly effective and orally active agonist targeting the peripherally restricted cannabinoid 1 receptor (CB1R). It exhibits pronounced analgesic properties, efficiently suppressing both chemotherapy-induced peripheral neuropathy pain symptoms and cancer-induced bone pain.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
1 mg | 在庫あり | ¥ 80,500 |
5 mg | 在庫あり | ¥ 190,000 |
10 mg | 在庫あり | ¥ 259,500 |
25 mg | 在庫あり | ¥ 365,000 |
50 mg | 在庫あり | ¥ 454,500 |
100 mg | 在庫あり | ¥ 574,000 |
説明 | PrNMI is a highly effective and orally active agonist targeting the peripherally restricted cannabinoid 1 receptor (CB1R). It exhibits pronounced analgesic properties, efficiently suppressing both chemotherapy-induced peripheral neuropathy pain symptoms and cancer-induced bone pain. |
In vitro | PrNMI (1 nM-1 μM; 24 h) shows no effects on the viability of 66.1 breast tumor cells in vitro.[2] |
In vivo |
PrNMI (0.25 mg/kg; Intraplantar ipsilateral administration; i.p.; CIPN rat model) causes significantly greater suppression in mechanical but not cold allodynia on the ipsilateral paw compared to contralateral paw or systemic administration at 2 h post-PrNMI.[1] PrNMI (3.0 mg/kg; i.g.; 48 h; CIPN rat model) dose-dependently suppresses CIPN symptoms in both male and female rats and is equally effective in male and female rats after oral administration.[1] PrNMI (1 mg/kg; p.o.; 48 h; CIPN rat model) exhibits anti-allodynic effects in CIPN mediated mainly by CB1Rs.[1] PrNMI (1 mg/kg; p.o.; daily for two weeks;) shows no significant tolerance to suppression of both mechanical and cold allodynia during the two-week testing period.[1] PrNMI (0.1, 0.3, and 0.6 mg/kg; i.p.) results in a significant, time-related reduction of flinching but not guarding in a dose-dependent manner. This suppression of flinching starts 1 hour post-injection and persists for at least 5 hours.[2] |
分子量 | 409.56 |
分子式 | C29H31NO |
CAS No. | 1541244-33-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 1mg/ml, Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PrNMI 1541244-33-0 GPCR/G Protein Cannabinoid Receptor Inhibitor inhibitor inhibit